-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Editas Medicine, Lowers Price Target to $4

Benzinga·05/13/2025 12:28:34
Listen to the news
Baird analyst Joel Beatty maintains Editas Medicine (NASDAQ:EDIT) with a Outperform and lowers the price target from $8 to $4.